356 related articles for article (PubMed ID: 16500715)
21. [Melanocortin system].
Levitskaia NG; Kamenskiĭ AA
Usp Fiziol Nauk; 2009; 40(1):44-65. PubMed ID: 19326848
[TBL] [Abstract][Full Text] [Related]
22. The MC4 receptor and control of appetite.
Adan RA; Tiesjema B; Hillebrand JJ; la Fleur SE; Kas MJ; de Krom M
Br J Pharmacol; 2006 Dec; 149(7):815-27. PubMed ID: 17043670
[TBL] [Abstract][Full Text] [Related]
23. Pro-opiomelanocortin and weight regulation: from mice to men.
Boston BA
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1409-16. PubMed ID: 11837494
[TBL] [Abstract][Full Text] [Related]
24. Mutations in the carboxyl terminus of the agouti protein decrease agouti inhibition of ligand binding to the melanocortin receptors.
Kiefer LL; Ittoop OR; Bunce K; Truesdale AT; Willard DH; Nichols JS; Blanchard SG; Mountjoy K; Chen WJ; Wilkison WO
Biochemistry; 1997 Feb; 36(8):2084-90. PubMed ID: 9047307
[TBL] [Abstract][Full Text] [Related]
25. Proteochemometric analysis of small cyclic peptides' interaction with wild-type and chimeric melanocortin receptors.
Kontijevskis A; Petrovska R; Mutule I; Uhlen S; Komorowski J; Prusis P; Wikberg JE
Proteins; 2007 Oct; 69(1):83-96. PubMed ID: 17557335
[TBL] [Abstract][Full Text] [Related]
26. Current trends in the structure-activity relationship studies of the endogenous agouti-related protein (AGRP) melanocortin receptor antagonist.
Wilczynski AM; Joseph CG; Haskell-Luevano C
Med Res Rev; 2005 Sep; 25(5):545-56. PubMed ID: 16044415
[TBL] [Abstract][Full Text] [Related]
27. Functional characterization of the modified melanocortin peptides responsible for ligand selectivity at the human melanocortin receptors.
Chen M; Georgeson KE; Harmon CM; Haskell-Luevano C; Yang Y
Peptides; 2006 Nov; 27(11):2836-45. PubMed ID: 16730390
[TBL] [Abstract][Full Text] [Related]
28. Melanocortin receptors and antagonists regulate pigmentation and body weight.
Jordan SA; Jackson IJ
Bioessays; 1998 Aug; 20(8):603-6. PubMed ID: 9780833
[TBL] [Abstract][Full Text] [Related]
29. Linkage and segregation analysis of black and brindle coat color in domestic dogs.
Kerns JA; Cargill EJ; Clark LA; Candille SI; Berryere TG; Olivier M; Lust G; Todhunter RJ; Schmutz SM; Murphy KE; Barsh GS
Genetics; 2007 Jul; 176(3):1679-89. PubMed ID: 17483404
[TBL] [Abstract][Full Text] [Related]
30. Anticatabolic properties of melanocortin-4 receptor antagonists.
Madison LD; Marks DL
Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):196-200. PubMed ID: 16607116
[TBL] [Abstract][Full Text] [Related]
31. Melanocortin receptor binding determinants in the agouti protein.
Kiefer LL; Veal JM; Mountjoy KG; Wilkison WO
Biochemistry; 1998 Jan; 37(4):991-7. PubMed ID: 9454589
[TBL] [Abstract][Full Text] [Related]
32. A concise synthesis of 1,4-dihydro-[1,4]diazepine-5,7-dione, a novel 7-TM receptor ligand core structure with melanocortin receptor agonist activity.
Szewczyk JR; Laudeman CP; Sammond DM; Villeneuve M; Minick DJ; Grizzle MK; Daniels AJ; Andrews JL; Ignar DM
Bioorg Med Chem; 2010 Mar; 18(5):1822-33. PubMed ID: 20172734
[TBL] [Abstract][Full Text] [Related]
33. A review of melanocortin receptor small molecule ligands.
Todorovic A; Haskell-Luevano C
Peptides; 2005 Oct; 26(10):2026-36. PubMed ID: 16051395
[TBL] [Abstract][Full Text] [Related]
34. The yellow mouse obesity syndrome and mechanisms of agouti-induced obesity.
Moussa NM; Claycombe KJ
Obes Res; 1999 Sep; 7(5):506-14. PubMed ID: 10509609
[TBL] [Abstract][Full Text] [Related]
35. Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.
Fleck BA; Chen C; Yang W; Huntley R; Markison S; Nickolls SA; Foster AC; Hoare SR
Biochemistry; 2005 Nov; 44(44):14494-508. PubMed ID: 16262250
[TBL] [Abstract][Full Text] [Related]
36. Gene expression analysis of melanocortin system in vitiligo.
Kingo K; Aunin E; Karelson M; Philips MA; Rätsep R; Silm H; Vasar E; Soomets U; Kõks S
J Dermatol Sci; 2007 Nov; 48(2):113-22. PubMed ID: 17651944
[TBL] [Abstract][Full Text] [Related]
37. New insights into G-protein-coupled receptor signaling from the melanocortin receptor system.
Rana BK
Mol Pharmacol; 2003 Jul; 64(1):1-4. PubMed ID: 12815154
[No Abstract] [Full Text] [Related]
38. Cachexia: lessons from melanocortin antagonism.
Deboer MD; Marks DL
Trends Endocrinol Metab; 2006 Jul; 17(5):199-204. PubMed ID: 16750633
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity.
Tao YX
Mol Cell Endocrinol; 2005 Jul; 239(1-2):1-14. PubMed ID: 15975705
[TBL] [Abstract][Full Text] [Related]
40. The early origin of melanocortin receptors, agouti-related peptide, agouti signalling peptide, and melanocortin receptor-accessory proteins, with emphasis on pufferfishes, elephant shark, lampreys, and amphioxus.
Västermark A; Schiöth HB
Eur J Pharmacol; 2011 Jun; 660(1):61-9. PubMed ID: 21208605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
